Vaccination against Respiratory Infections in the Immunosenescent Older Adult Population: Challenges and Opportunities

Abstract

Respiratory infections are associated with a huge burden of disease every year and disproportionately affect older adults, namely those aged 65 years and older. Older adults are at increased risk of infections compared with their younger counterparts, and once infected, have a higher risk of experiencing severe disease course, complications, and long-term sequelae. Therefore, vaccination is clearly a key strategy to prevent infection and its attendant negative consequences. We review here the burden of common respiratory diseases in older adults, namely influenza, pneumococcal disease, and respiratory syncytial virus. We then review some of the challenges facing immunization of older adults, namely immunosenescence, inflammaging, and low vaccine uptake. Next, potential opportunities for overcoming these challenges are reviewed, including the use of higher antigen doses and/or adjuvants in vaccine formulations for older adults, and the potential of multiomics analyses to improve development, performance, and implementation of vaccines.

Keywords

respiratory infection - vaccination - influenza - pneumococcal disease - respiratory syncytial virus - older adults

Publication History

Accepted Manuscript online:
11 December 2024

Article published online:
30 January 2025

• References

• 1 Wagner A, Weinberger B. Vaccines to prevent infectious diseases in the older population: immunological challenges and future perspectives. Front Immunol 2020; 11: 717
• 2 Shattock AJ, Johnson HC, Sim SY. et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet 2024; 403 (10441): 2307-2316
• 3 Talbird SE, La EM, Carrico J. et al. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum Vaccin Immunother 2021; 17 (02) 332-343
• 4 European Centre for Disease Prevention and Control. Seasonal influenza vaccination recommendations and coverage rates in EU/EEA Member States—an overview of vaccination recommendations for 2021–22 and coverage rates for the 2018–19 to 2020–21 influenza seasons. Stockholm: ECDC. Accessed March 17, 2024 at: https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-recommendations-and-coverage-rates-eueea-member 2023
• 5 Hung MC, Srivastav A, Lu PJ. et al. Vaccination coverage among adults in the United States, National Health Interview Survey, 2021. Accessed August 2, 2024 at: https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/vaccination-coverage-adults-2021.html#
• 6 Coalition for Life Course Immunisation, International Longevity Centre UK. Pneumococcal Vaccination Atlas. Accessed August 7, 2024 at: https://pneumoniaatlas.org/
• 7 Mallah N, Urbieta AD, Rivero-Calle I. et al. New vaccines for chronic respiratory patients. Arch Bronconeumol 2024; 60 (09) 565-575
• 8 Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc 2014; 11 (03) 404-406
• 9 World Health Organization. Ageing and health. Key Facts. Geneva: World Health Organization; . Accessed March 10, 2024 at: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health 2022
• 10 Maggi S, Andrew MK, de Boer A. Podcast: influenza-associated complications and the impact of vaccination on public health. Infect Dis Ther 2024; 13 (03) 413-420
• 11 World Health Organization. Influenza (seasonal). Key facts. Geneva: World Health Organization; . Accessed August 4, 2024 at: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) 2023
• 12 GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 2019; 7 (01) 69-89
• 13 Lemaitre M, Fouad F, Carrat F. et al. Estimating the burden of influenza-related and associated hospitalizations and deaths in France: an eight-season data study, 2010-2018. Influenza Other Respir Viruses 2022; 16 (04) 717-725
• 14 Antonelli Incalzi R, Consoli A, Lopalco P. et al. Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion. Intern Emerg Med 2024; 19 (03) 619-640
• 15 Chow EJ, Rolfes MA, O'Halloran A. et al. Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study. Ann Intern Med 2020; 173 (08) 605-613
• 16 Kwong JC, Schwartz KL, Campitelli MA. et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018; 378 (04) 345-353
• 17 Behrouzi B, Bhatt DL, Cannon CP. et al. Association of influenza vaccination with cardiovascular risk: a meta-analysis. JAMA Netw Open 2022; 5 (04) e228873
• 18 Yedlapati SH, Khan SU, Talluri S. et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc 2021; 10 (06) e019636
• 19 Poudel S, Shehadeh F, Zacharioudakis IM. et al. The effect of influenza vaccination on mortality and risk of hospitalization in patients with heart failure: a systematic review and meta-analysis. Open Forum Infect Dis 2019; 6 (04) ofz159
• 20 Modin D, Lassen MCH, Claggett B. et al. Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: a meta-analysis. Eur J Heart Fail 2023; 25 (09) 1685-1692
• 21 Fröbert O, Götberg M, Erlinge D. et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation 2021; 144 (18) 1476-1484
• 22 Demurtas J, Celotto S, Beaudart C. et al. The efficacy and safety of influenza vaccination in older people: an umbrella review of evidence from meta-analyses of both observational and randomized controlled studies. Ageing Res Rev 2020; 62: 101118
• 23 Morales KF, Brown DW, Dumolard L. et al. Seasonal influenza vaccination policies in the 194 WHO Member States: the evolution of global influenza pandemic preparedness and the challenge of sustaining equitable vaccine access. Vaccine X 2021; 8: 100097
• 24 Ortiz JR, Perut M, Dumolard L. et al. A global review of national influenza immunization policies: analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization. Vaccine 2016; 34 (45) 5400-5405
• 25 Grohskopf LA, Blanton LH, Ferdinands JM. et al. Prevention and Control of Seasonal Influenza with Vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 influenza season. MMWR Recomm Rep 2022; 71 (01) 1-28
• 26 Public Health Agency of Canada. Influenza vaccines. Canadian Immunization Guide. Ottawa (ON): Government of Canada; 2023. . Accessed March 17, 2024 at: https://wwwcanadaca/en/public-health/services/canadian-immunization-guidehtml
• 27 Al-Jabri M, Rosero C, Saade EA. Vaccine-preventable diseases in older adults. Infect Dis Clin North Am 2023; 37 (01) 103-121
• 28 GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018; 18 (11) 1191-1210
• 29 Grant LR, Meche A, McGrath L. et al. Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis 2023; 10 (05) ofad192
• 30 Elias C, Nunes MC, Saadatian-Elahi M. Epidemiology of community-acquired pneumonia caused by Streptococcus pneumoniae in older adults: a narrative review. Curr Opin Infect Dis 2024; 37 (02) 144-153
• 31 Scott P, Haranaka M, Choi JH. et al; STRIDE-6 study group. A phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or older (Stride-6). Clin Infect Dis 2024; ciae383
• 32 Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T. et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014; 58 (07) 909-917
• 33 Bonten MJ, Huijts SM, Bolkenbaas M. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372 (12) 1114-1125
• 34 van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJ. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin Infect Dis 2015; 61 (12) 1835-1838
• 35 Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One 2017; 12 (01) e0169368
• 36 Marques Antunes M, Duarte GS, Brito D. et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes 2021; 7 (01) 97-106
• 37 Shen L, Jhund PS, Anand IS. et al. Incidence and outcomes of pneumonia in patients with heart failure. J Am Coll Cardiol 2021; 77 (16) 1961-1973
• 38 European Centre for Disease Prevention and Control. Vaccine scheduler: pneumococcal disease: recommended vaccinations. Stockholm: ECDC; 2024. . Accessed August 4, 2024 at: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1
• 39 Kobayashi M, Pilishvili T, Farrar JL. et al. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep 2023; 72 (03) 1-39
• 40 McDonagh TA, Metra M, Adamo M. et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42 (36) 3599-3726
• 41 Heidenreich PA, Bozkurt B, Aguilar D. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79 (17) e263-e421
• 42 Li Y, Reeves RM, Wang X. et al; RSV Global Epidemiology Network, RESCEU investigators. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health 2019; 7 (08) e1031-e1045
• 43 Shi T, Denouel A, Tietjen AK. et al; RESCEU Investigators. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis 2020; 222 (Suppl. 07) S577-S583
• 44 Kujawski SA, Whitaker M, Ritchey MD. et al. Rates of respiratory syncytial virus (RSV)-associated hospitalization among adults with congestive heart failure-United States, 2015-2017. PLoS One 2022; 17 (03) e0264890
• 45 Li Y, Kulkarni D, Begier E. et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther 2023; 12 (04) 1137-1149
• 46 Kenmoe S, Nair H. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis 2024; 37 (02) 129-136
• 47 Papi A, Ison MG, Langley JM. et al; AReSVi-006 Study Group. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388 (07) 595-608
• 48 Ison MG, Papi A, Athan E. et al; AReSVi-006 Study Group. Efficacy and safety of respiratory syncytial virus (RSV) prefusion f protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis 2024; 78 (06) 1732-1744
• 49 Walsh EE, Pérez Marc G, Zareba AM. et al; RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388 (16) 1465-1477
• 50 Wilson E, Goswami J, Baqui AH. et al; ConquerRSV Study Group. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med 2023; 389 (24) 2233-2244
• 51 Melgar M, Britton A, Roper LE. et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72 (29) 793-801
• 52 European Centre for Disease Prevention and Control. Vaccine scheduler: RSV: Recommended vaccinations. Stockholm: ECDC; 2024. . Accessed August 4, 2024 at: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=53&SelectedCountryIdByDisease=-1
• 53 Cadar AN, Martin DE, Bartley JM. Targeting the hallmarks of aging to improve influenza vaccine responses in older adults. Immun Ageing 2023; 20 (01) 23
• 54 Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol 2018; 40: 83-94
• 55 Simmons SR, Tchalla EYI, Bhalla M, Bou Ghanem EN. The age-driven decline in neutrophil function contributes to the reduced efficacy of the pneumococcal conjugate vaccine in old hosts. Front Cell Infect Microbiol 2022; 12: 849224
• 56 Frasca D, Blomberg BB. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immun Ageing 2020; 17 (01) 37
• 57 Vetrano DL, Triolo F, Maggi S. et al. Fostering healthy aging: the interdependency of infections, immunity and frailty. Ageing Res Rev 2021; 69: 101351
• 58 Franceschi C, Bonafè M, Valensin S. et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244-254
• 59 Franceschi C, Salvioli S, Garagnani P, de Eguileor M, Monti D, Capri M. Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity. Front Immunol 2017; 8: 982
• 60 Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008; 8 (09) 737-744
• 61 McElhaney JE, Xie D, Hager WD. et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176 (10) 6333-6339
• 62 Ruiz-Palacios GM, Leroux-Roels G, Beran J. et al; Influence65 study group. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: a phase 3, randomized trial and post-hoc correlate of protection analysis. Hum Vaccin Immunother 2016; 12 (12) 3043-3055
• 63 Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N. The establishment of surrogates and correlates of protection: useful tools for the licensure of effective influenza vaccines?. Hum Vaccin Immunother 2018; 14 (03) 647-656
• 64 Plotkin SA. Recent updates on correlates of vaccine-induced protection. Front Immunol 2023; 13: 1081107
• 65 Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12 (01) 36-44
• 66 King DF, Groves H, Weller C. et al. Realising the potential of correlates of protection for vaccine development, licensure and use: short summary. NPJ Vaccines 2024; 9 (01) 82
• 67 Tan PS, Patone M, Clift AK. et al. Factors influencing influenza, pneumococcal and shingles vaccine uptake and refusal in older adults: a population-based cross-sectional study in England. BMJ Open 2023; 13 (03) e058705
• 68 Fuller HR, Huseth-Zosel A, Van Vleet B, Carson PJ. Barriers to vaccination among older adults: demographic variation and links to vaccine acceptance. Aging Health Res 2024; 4: 100176
• 69 Centers for Disease Control and Prevention. Flu vaccination coverage, United States, 2023–24 influenza season. Accessed November 11, 2024 at: https://www.cdc.gov/fluvaxview/coverage-by-season/2023-2024.html 2024
• 70 Veronese N, Zambon N, Noale M, Maggi S. Poverty and influenza/pneumococcus vaccinations in older people: data from the Survey of Health, Ageing and Retirement in Europe (SHARE) study. Vaccines (Basel) 2023; 11 (09) 11
• 71 Suitner C, Salvador Casara BG, Maggi S, Baldo V. An independent study to compare compliance, attitudes, knowledge, and sources of knowledge about pneumococcal vaccinations among an Italian sample of older adults. Vaccines (Basel) 2022; 10 (04) 10
• 72 Ecarnot F, Maggi S, Michel JP. Strategies to improve vaccine uptake throughout adulthood. Interdiscip Top Gerontol Geriatr 2020; 43: 234-248
• 73 Johansen ND, Vaduganathan M, Bhatt AS. et al. Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial. Lancet 2023; 401 (10382): 1103-1114
• 74 Su Z, Cheshmehzangi A, McDonnell D, da Veiga CP, Xiang YT. Mind the “vaccine fatigue”. Front Immunol 2022; 13: 839433
• 75 Doherty TM, Ecarnot F, Gaillat J, Privor-Dumm L. Nonstructural barriers to adult vaccination. Hum Vaccin Immunother 2024; 20 (01) 2334475
• 76 Pattyn J, Del Riccio M, Bechini A. et al. The Adult Immunization Board (AIB): a new platform to provide multidisciplinary guidelines for the implementation and optimization of adult immunization in Europe. Vaccine 2024; 42 (01) 1-3
• 77 Pepin S, Nicolas JF, Szymanski H. et al; QHD00011 study team. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial. Hum Vaccin Immunother 2021; 17 (12) 5475-5486
• 78 Skaarup KG, Lassen MCH, Modin D. et al. The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: a meta-analysis of evidence from randomized trials. J Infect 2024; 89 (01) 106187
• 79 Lee JKH, Lam GKL, Yin JK, Loiacono MM, Samson SI. High-dose influenza vaccine in older adults by age and seasonal characteristics: systematic review and meta-analysis update. Vaccine X 2023; 14: 100327
• 80 O'Hagan DT, Friedland LR, Hanon E, Didierlaurent AM. Towards an evidence based approach for the development of adjuvanted vaccines. Curr Opin Immunol 2017; 47: 93-102
• 81 Zhao T, Cai Y, Jiang Y. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther 2023; 8 (01) 283
• 82 O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011; 10 (04) 447-462
• 83 Cohet C, van der Most R, Bauchau V. et al. Safety of AS03-adjuvanted influenza vaccines: a review of the evidence. Vaccine 2019; 37 (23) 3006-3021
• 84 Verma SK, Mahajan P, Singh NK. et al. New-age vaccine adjuvants, their development, and future perspective. Front Immunol 2023; 14: 1043109
• 85 Didierlaurent AM, Laupèze B, Di Pasquale A, Hergli N, Collignon C, Garçon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines 2017; 16 (01) 55-63
• 86 Sugrue JA, Duffy D. Systems vaccinology studies - achievements and future potential. Microbes Infect 2024; 26 (07) 105318